
Imiclara5%
Unimed Unihealth MFG. Ltd.
Imiquimod cream is a topical immune response modifier approved for three distinct dermatological conditions.
Imiquimod cream is a topical immune response modifier approved for three distinct dermatological conditions. The specific product strength and treatment regimen differ by indication, so the exact product and schedule prescribed by a physician must be used for each condition.
Imiquimod has not been shown effective for molluscum contagiosum and is not indicated for urethral, intra-vaginal, cervical, rectal, or intra-anal human papillomavirus (HPV) disease. Use for actinic keratosis or superficial basal cell carcinoma is not recommended in immunosuppressed patients, as safety and efficacy have not been established in that population.
The dose, frequency, and duration of Imiquimod treatment depend on the specific indication and product strength. The regimens below are typical; the treating physician's specific instructions should always be followed.
| Indication | Typical Regimen | Maximum Duration |
|---|---|---|
| External genital/perianal warts (5% cream) | Apply a thin layer 3 times per week (e.g., Mon-Wed-Fri) at bedtime; leave on 6-10 hours, then wash off with mild soap and water. | Until warts clear, up to 16 weeks per wart episode |
| External genital/perianal warts (3.75% cream) | Apply once daily at bedtime; leave on approximately 8 hours, then wash off. | Up to 8 weeks |
| Actinic keratosis (5% cream) | Apply twice weekly (e.g., Mon and Thu) at bedtime to the face or scalp; leave on approximately 8 hours, then wash off. | 16 weeks |
| Actinic keratosis (2.5%/3.75% cream) | Apply once daily at bedtime for two 2-week treatment cycles separated by a 2-week treatment-free interval; leave on approximately 8 hours, then wash off. | Two 2-week cycles |
| Superficial basal cell carcinoma (5% cream only) | Apply 5 times per week at bedtime to the tumour and a 1 cm margin of surrounding skin; leave on approximately 8 hours, then wash off. | 6 weeks |
If a severe local skin reaction occurs, a rest period of several days may be needed before resuming treatment, on a physician's advice. See Precautions and Warnings for details on expected local skin reactions.
Local skin reactions at the application site are expected and common as part of how Imiquimod works, including redness (erythema), erosion, excoriation/flaking, swelling (oedema), scabbing/crusting, itching, and burning. These can be intense, particularly during superficial basal cell carcinoma treatment, and may require a temporary rest from treatment (see Precautions and Warnings).
Patients should contact their physician if local reactions become severe or intolerable, or if systemic symptoms occur.
Imiquimod is contraindicated in patients with known hypersensitivity to imiquimod or to any component of the cream formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.